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Klassevirus is a proposed new genus of picornavirus that has been associated with pediatric diarrhea. In this
study, we used recombinant klassevirus 3C protease as the capture antigen for an indirect serological enzymelinked immunosorbent assay (ELISA). Four of six klassevirus reverse transcription (RT)-PCR-positive individuals demonstrated seroconversion against the 3C protease, suggesting that klassevirus infection and
replication occur in humans. Additional screening of 353 samples from an age-banded serological cohort from
two St. Louis hospitals indicated a seroprevalence of 6.8%.
Klassevirus is the prototype member of a new picornavirus
genus that has recently been discovered in human stool (3, 4,
7). Phylogenetic analysis shows klassevirus is most closely related to Aichi virus, a known cause of oyster-associated gastroenteritis in humans. Molecular detection studies have found
klassevirus in pediatric stool and municipal sewage from the
United States, Spain, Australia, Tunisia, and Nigeria (3, 4, 7).
A small case control study found a statistically significant association between klassevirus and pediatric diarrhea (7). Furthermore, klassevirus RNA has been detected in high titer in
pediatric stool (3). However, klassevirus has not yet been detected in any sterile sites in the human body, and thus it is still
not clear whether the presence of the virus in stool represents
a bona fide human infection.
In this study, we established a serological assay for klassevirus infection using recombinant klassevirus 3C protease to
demonstrate seroconversion and human infection and to
test for seroprevalence in an age-banded pediatric cohort
from hospitals in the St. Louis area. Klassevirus 3C protease
shares only 38% amino acid identity and only one potential
7-mer epitope with its closest relative, the 3C protease of
Aichi virus. Previous studies of hepatitis A virus (HAV), a
prototypic picornavirus, indicate that antibodies are made
against the picornaviral 3C protease during bona fide picornavirus replication and thus can distinguish between vaccinated and actively infected chimpanzees, humans, and tamarins (5, 9).

MATERIALS AND METHODS
Expression and purification of 3C protease. The klassevirus 3C protease gene
(nucleotides [nt] 5825 to 6409 from strain 2394-01; NC_012986.1) flanked with
NdeI and XhoI restriction sites was amplified from stool total RNA by reverse
transcription (RT)-PCR with the following primers: klasse3C-NdeI (5⬘-CATAT
GGGTTTCGACCCTGCCGTCATGAAG-3⬘ and klasse3C-XhoI (5⬘-CTCGAG
TCATCACTGAGGTGTGGCCAGGTTAGAGA-3⬘) (restriction sites italicized
and stop codons underlined). The resulting product was sequence confirmed,
digested with NdeI and XhoI, and subcloned into NdeI/XhoI-digested pET15b
(Novagen), which contains a 6⫻His tag on the N terminus. The sequenceconfirmed pET15b vector containing the klassevirus 3C gene was transformed
into Escherichia coli BL21(DE3)LysS/pRIL and recombinant 6⫻His-klassevirus
3C protein expression was induced with 1 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) at 37°C for 5 h. Cells were lysed in 150 mM NaCl, 25 mM Tris, pH
8.0, 5 mM imidazole, 2 mM ␤-mercaptoethanol, and 5% glycerol with 0.5 mg/ml
lysozyme for 30 min in ice and 3 min of sonication (Branson Sonifier 250) at 60%
power. 6⫻His-klassevirus 3C protein was purified from cell lysates via Ni-nitrilotriacetic acid (NTA) column chromatography. The resulting eluate was then concentrated using a 10-kDa Amicon Ultra (Millipore, Billerica, MA) and loaded on a
120-ml Superdex 200 gel filtration column (GE LifeSciences; Piscataway, NJ). Elution fractions were quantitated using 280-nm absorbance on a Nanodrop, and the
91-ml fraction was used for enzyme-linked immunosorbent assay (ELISA) experiments. SDS-PAGE was performed using 4 to 12% Bis-Tris NuPage gels (Invitrogen;
Carlsbad, CA), and silver staining was performed using SilverXpress (Invitrogen).
Two milligrams of purified 6⫻His-klassevirus 3C was used for polyclonal antibody
generation in rabbits (Pacific Immunology; Ramona, CA).
RT-PCR screening of Indian samples. Community- and hospital-based samples (n ⫽ 416) collected in Vellore, India, from 2005 to 2006 were screened for
klassevirus. The community-based samples were from a birth cohort followed for
3 years. In this cohort, stool samples were collected every 2 weeks and with every
episode of diarrhea. Additionally, serum samples were obtained every 3 months
during the first 2 years and every 6 months during the third year of the study (8).
The hospital-based samples were from a single-point collection of diarrheal stool
for surveillance of children under the age of 5 years hospitalized for acute
gastroenteritis (6).
RNA was extracted from 200 l of an ⬃20% fecal suspension by the Boom
method and eluted in 40 l of water (1). A Qiagen one-step RT-PCR kit
(Qiagen, Valencia, CA) was used to screen 3 l of extracted material from each
sample, using primers LG0098 (5⬘-CGTCAGGGTGTTCGTGATTA-3⬘) and
LG0093 (5⬘-AGAGAGAGCTGTGGAGTAATTAGTA-3⬘). These primers target the 2C region of klassevirus 1 and are expected to generate a 345-bp amplicon. RT-PCRs were performed using Qiagen one-step kit under the following
conditions: 30 min for the RT step, with a 94°C hold for 10 min, followed by 40
cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 60 s. Some amplicons were
cloned into pCR4 (Invitrogen) and sequenced using standard Sanger sequencing
technology (GenBank accession no. GU992865 to GU992870).
St. Louis serum cohort. We analyzed 353 deidentified serum samples from
patients 1 day to 79 years of age collected from St. Louis Children’s Hospital
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and Barnes-Jewish Hospital in St. Louis, MO, from November 2007 through
October 2008 for antibodies against the 3C protease from klassevirus. Serum
samples were kindly provided by Greg Storch (St. Louis Children’s Hospital)
and Mitchell Scott (Barnes-Jewish Hospital). The patients were age stratified,
and 30 samples were used for each pediatric age group, except for the groups
6 months to 1 year and 6 to 9 years, for which 29 samples were available. For
the adult age groups, the following numbers of samples were available: 7
samples for 20 to 34 years, 15 samples for 35 to 49 years, 20 samples for 50
to 64 years, and 13 samples for 65 to 79 years. Collection of samples and
clinical data were approved by the Human Research Protection Office of
Washington University in St. Louis, School of Medicine.
ELISA. Purified klassevirus 3C protein (0.15 g/well) was coated overnight
at 4°C in 50 l phosphate-buffered saline (PBS) in Maxisorp 96-well microtiter plates (Nunc, Naperville, IL). Wells were washed twice with PBST (PBS
containing 0.05% Tween 20) and blocked with blocking buffer (PBST containing 1% bovine serum albumin) for 2 h at room temperature. Wells were
washed twice again with PBST and incubated with serum samples diluted
1:100 in blocking buffer in triplicate overnight at 4C. Serum samples for
competition experiments were diluted 1:100 in blocking buffer and preincubated with 0.6 g protein overnight at 4C. Plates were washed four times with
PBST and incubated with horseradish peroxidase (HRP)-conjugated antihuman IgG antibody (Invitrogen) diluted 1:10,000 in 50 l blocking buffer for
2 h at room temperature. Plates were then washed four times with PBST and
incubated with 50 l Ultra-TMB (Sigma; St. Louis, MO) for 30 min at room
temperature. An equal volume of 2 M H2SO4 was added to stop the reaction,
and the endpoint optical density values at 450 nm (OD450) were read immediately on a SpectraMax M2 plate reader. Statistical tests were done using a
two-sample t test.
Western confirmation was performed for two matched serum samples from
India by running 5 g of purified klassevirus 3C protease on 4 to 12% Bis-Tris
NuPage gels, transferring the samples using the XCell II blot module, staining them overnight at 4°C using 5 l of human serum diluted 1:200 into 1 ml
of 5% milk in PBST, and developing them with Western Lightning enhanced
luminal reagent. Western blots were scanned on an Epson Perfection V350
photo scanner and quantitated using Licor Odyssey 2.1 software.

RESULTS
Purification of klassevirus 3C protease. Klassevirus 3C protease was expressed as an N-terminal 6⫻His-tagged fusion

protein, purified using Ni-NTA affinity chromatography, and
followed by gel filtration fast protein liquid chromatography
(FPLC). SDS-PAGE analysis with Coomassie stain and silver
stain was used to confirm the purity of products at each stage
(Fig. 1). The inclusion of reducing agents (at least 5 mM
␤-mercaptoethanol) was the most important factor in increasing the solubility of the product purified off the Ni-NTA column. The inclusion of 20% glycerol, 10 mM PMSF, 1⫻ Roche
proteinase inhibitor, or 1% Triton X did not prevent the elution from precipitating, as determined by visual inspection.
The purified 6⫻His-klassevirus 3C protein was used as a capture antigen for an indirect ELISA for serological analysis of
klassevirus infection.
Detection of klassevirus-positive stool samples in an Indian
cohort. Sixteen of the 203 community-based stool samples and
9 of the 213 hospital-based stool samples were positive by
RT-PCR screening. Sequence was recovered from four of the
community-based positive samples and two of the hospitalbased positive samples.
Serological analysis of positive control samples and St.
Louis cohort. Matched preinfection and convalescent-phase
human sera from klassevirus-positive Indian children who had
PCR-positive klassevirus detected in stool were available for
serological testing. A statistically significant (P ⬍ 0.005) increase in OD450 could be demonstrated in four of the six
matched samples for as long as 11 months after klassevirus was
detected in stool (Fig. 2A). Western blot analysis confirmed
seroconversion between matched preinfection and postinfection serum samples 2246-5672 and 3516-5475, the only samples
for which enough serum remained to attempt Western confirmation (Fig. 2B).
We next screened 353 age-banded serum samples from two
St. Louis hospitals (Fig. 3). To control for plate-to-plate vari-
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FIG. 1. Purification of klassevirus 3C protease. N-terminal His-tagged klassevirus 3C protease was expressed in E. coli and purified by
Ni-NTA chromatography (A and B). Ni-NTA eluates were further purified by gel filtration chromatography using a Superdex 200 column
(C). The 91-ml fraction was tested via silver stain to confirm purity of klassevirus 3C protease (D). Lane M, molecular mass markers.
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ation, a single control serum sample from a healthy donor was
analyzed on every ELISA plate. The coefficient of variance for
this sample was 8.8% across the 12 plates, indicating a high
level of consistency for the assay. Incubation of the single
control serum sample with recombinant Taq polymerase as the
capture reagent resulted in a comparable OD450 with no plated
antigen (OD450, ⬍0.10). The mean OD450 of this serum sample
in the St. Louis cohort was equivalent to its average OD450
when run with the matched Indian serum samples (coefficient

of variation [CV], 3%). The median OD450 for the St. Louis
children’s hospital samples was 0.114, while the mean OD450
for the 0- to 6-month samples was 0.093 (standard deviation
[SD], 0.023). Twenty-six (8.7%) of the pediatric St. Louis samples and 12 (21.8%) of the adult serum samples had an average
OD450 that was greater than the highest OD450 for a preinfection Indian serum sample. Using a specific OD450 cutoff of
0.300 (a value that separates preinfection and postinfection
OD450 values in the seroconverting Indian samples) yielded 16
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FIG. 2. Klassevirus 3C ELISA for matched serum samples from klassevirus PCR-positive children from India. Endpoint OD450 values for
matched preinfection serum samples (1:100 dilution; white) and postinfection serum samples (1:100 dilution; shaded) are grouped together, along
with polyclonal rabbit antisera generated against klassevirus 3C and blocking buffer (A). The dotted line indicates an OD450 cutoff value of 0.30
that separates pre- and postinfection OD450 values. Asterisks indicate significant increases in OD450 (P ⬍ 0.005). Remaining serum was available
from two matched serum samples (2246 and 3516) for Western confirmation, which showed a 4-fold and 8-fold increase in signal between pre- and
post-klassevirus infection serum samples at a dilution of 1:200, respectively (B).
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(5.3%) seropositives in the pediatric St. Louis cohort and eight
(14.5%) seropositives in the adult cohort. There was no significant association between klassevirus seropositivity and sex in
either the pediatric or adult cohort.
DISCUSSION
The data in this study indicate that IgG antibodies are generated against the 3C protease after klassevirus infection. This
represents the first demonstration of a human antibody response to a klassevirus antigen and suggests that bona fide
human infection by klassevirus occurs. Based on the available
convalescent-phase serum samples, IgG antibodies could be
detected in some instances as long as 7 months after infection.
It is unclear how long the antibody response to klassevirus 3C
persists, and more extensive studies, using longitudinal serum
samples are needed to address this issue.
Screening of an age-banded cohort of 353 serum samples
from St. Louis Children’s Hospital yielded only a handful of
positive samples, using a cutoff value defined by the average of
the preinfection samples from India. This observation suggests
either that the klassevirus infection rate in the United States is
quite low or that anti-klassevirus 3C antibodies may not be
long lived. To assess this further, a larger sample size and/or
serial samples taken from individuals with klassevirus confirmed stool samples would be required.
To date, klassevirus has only been detected via PCR of stool
and sewage samples (3, 4, 7). Importantly, 3C protease is not
present in picornaviral virions, and studies of hepatitis A experimental infections in chimpanzees indicate that anti-3C antibodies are only generated in an actively infected individual
(5). Thus, our data are consistent with the notion that klassevirus replicates in humans and is not merely a virus of some
human foodstuff.
No culture system for klassevirus has been described to date.
Thus, recombinant viral proteins are the only currently viable

capture reagents for determining seroprevalence. Attempts to
use capsid VP1 protein for serological analysis, as has been
used for other picornaviruses, were hindered by an inability to
refold the purified denatured protein. Our experience with
purification of VP1 is not atypical. Previous attempts have
required purification from inclusion bodies and subsequent
refolding on gel filtration columns (2, 10). Use of previous
published protocols for the purification of VP1 were not successful, although this does not preclude future optimization to
recover correctly folded protein (2, 10). Nonstructural proteins, such as 3C, have also been used to determine seroprevalence of picornaviruses (5). From a technical perspective, nonstructural proteins are more likely to be soluble than structural
proteins and are easier to assay for activity and correct folding.
Furthermore, detection of an immune response mediated
against nonstructural proteins that are not present in the virion
is suggestive of viral replication in vivo. Previous studies of
hepatitis A virus (HAV) infection also suggested the severity
of infection is correlated with the development of anti-3C
antibodies (5, 9). However, these studies also suggest that
there is heterogeneity in the development of anti-3C and antistructural protein antibodies. Not every infected individual will
develop anti-3C antibodies, even though anti-structural protein antibodies and evidence of clinical infection may develop.
In this study, we note that two of six klassevirus-infected individuals showed no increase in anti-3C antibody levels.
Unambiguously ascertaining the seroprevalence of new
agents such as klassevirus in a population is complicated by the
lack of true positive and negative controls. For example, the
infection history of the “preinfection” Indian serum samples
and the 0- to 6-month-olds in the St. Louis cohort is not known.
In this study, we made the assumption that the “preinfection”
Indian serum samples represent seronegative individuals to
create a specific cutoff value for seropositivity. Using these
criteria, a seroprevalence of 6.8% was found in 353 serum
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FIG. 3. Klassevirus 3C ELISA for 353 age-banded samples from St. Louis Children’s Hospital and Barnes-Jewish Hospital. Approximately 30
samples for each age band were included. A specific OD450 cutoff value of 0.30 based on the matched Indian serum in Fig. 2 suggested 24 (6.8%)
of the serum samples were seropositive for klassevirus.
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also like to know how often klassevirus can infect an individual
and whether neutralizing antibodies are generated. Of special
interest is the use of klassevirus serology to determine potential associations with clinical disease in humans aside from
diarrhea.
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samples from St. Louis. This seroprevalence is fairly low for a
virus that has, to date, only been found in young children. This
may be indicative of highly sporadic infection of klassevirus in
St. Louis or may be suggestive of a short-lived antibody response to the 3C protease, as indicated by an inconsistent
increase in seroprevalence with increasing age (Fig. 3). An
alternative way to analyze the seroprevalence would be to
assume that the 0- to 6-month samples are negative based on
their low OD450 values and extremely young age and to create
a common ELISA seropositivity cutoff 2 or 3 SDs above the
mean 0- to 6-month OD450. The number of seropositive samples using this method would be 121 (34.3%) or 85 (24%)
samples, respectively. However, using the 2-SD seropositive
cutoff would count five of the six preinfection matched Indian
serum samples as seropositive. This may be a reasonable conclusion given the higher detection of klassevirus by RT-PCR in
stool from Indian children than has been reported in the
United States (3, 4, 7). However, maternal antibodies would be
unlikely to account for any seropositivity in the preinfection
samples, as four of the six children were more than a year of
age at the date of serum collection.
In this study, a small number of longitudinal serum samples
(up to a year following the acute positive stool sample) from
klassevirus-infected individuals were tested, demonstrating
that high titers persist for at least 6 months. Ideally, a much
longer longitudinal cohort should be examined to define the
lifetime of an anti-klassevirus 3C response in a given individual. Studies on anti-3C antibodies from HAV suggest that
anti-3C antibodies remain detectable in serum for up to 15
months after infection (5). The possibility of short-lived anti-3C
antibody may explain why we failed to observe a clear upward
trend in seropositivity across different age bands, although
sample sizes for each age band were small and the adult population seemed to have a higher seroprevalence than the pediatric population. We also failed to observe seropositivity in
children ⬍6 months old, indicating a lack of maternally transmitted anti-3C antibodies in this population.
Future studies will be required to ascertain seroprevalence
across different populations, environments, and age bands.
Neutralization tests or virus-like particle-based ELISAs could
provide an orthogonal test for klassevirus serology. We would
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